OIPE
APR 05 2007
PATENT & TRADEMARK OFFICE

10693917

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of :

Edmond DIFFERDING et al. : **MAIL STOP: POST ISSUE**

Patent No. 6,911,461 :

Issued June 28, 2005 :

2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

PATENT OFFICE FEE TRANSMITTAL FORM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached hereto is a check in the amount of **$130.00** to cover Patent Office fees relating to filing the following attached papers:

Petition For Correction of Inventorship under 37 CFR 1.324 ..... $130.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Edmond DIFFERDING et al.

By _____
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Patentee

WMC/dlk
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
April 5, 2007

[Check No. 79750]

2003_1548

OIPE IAP59
APR 0 5 2007
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of :

Edmond DIFFERDING et al. :

Patent No. 6,911,461 : **MAIL STOP: POST ISSUE**

Issued June 28, 2005 :

2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

PETITION FOR CORRECTION OF INVENTORSHIP UNDER 37 CFR 1.324

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petition is hereby made for correction of inventorship in the above-identified U.S. patent.

Following a recent good faith examination, it was determined that the correct inventors of the claimed subject matter are only Benoit KENDA; Patrick PASAU and Benedicte LALLEMAND.

Accordingly, the following inventors should be deleted: Edmond DIFFERDING, Philippe MICHEL, Patrice TALAGA and Alain MATAGNE.

The error in inventorship arose without any deceptive intention on the part of the inventors and the Assignee. It is respectfully requested that a certificate naming only the actual inventors be issued.

Attached hereto is a statement from the current named inventors who have not submitted a statement under paragraph (b)(1) of 37 CFR 1.324, agreeing to the change of inventorship. See the attached Confirmatory Acknowledgement Agreement, signed by all of the current inventors and by an authorized representative of the Assignee. In particular, please see the first line on page 2 of the Agreement, which states that:

04/06/2007 JADDO1 00000009 6911461
01 FC:1464 130.00 OP

"IT HAS BEEN UNANIMOUSLY AGREED AND DETERMINED.

Following a good faith examination, it was determined that the invention(s) claimed in U.S. 6,911,461 B2 were solely conceived and reduced to practice by the 3 following inventors:

(i) Benoit KENDA

(ii) Patrick PASAU

(iii) Benedicte LALLEMAND

As a result of this examination the original designation of inventors of U.S. 6,911,461 B2 needs and shall be corrected".

The attached document also is signed by an authorized representative of the sole Assignee, agreeing to the change of inventorship.

A Statement Under 37 CFR 3.73(b) is enclosed.

The petition fee set forth in 37 CFR 1.20(b) of $130.00 is enclosed. The commissioner is authorized to charge any fee deficiency or refund any overpayment to the deposit account of the law firm of the undersigned representative, No. 23-0975.

Respectfully submitted,

Edmond DIFFERDING et al.

By _____
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Patentee

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 5, 2007

OIPE IAP59
APR 0 5 2007
PATENT & TRADEMARK OFFICE

CONFIRMATORY ACKNOWLEDGEMENT AGREEMENT

THIS AGREEMENT is made the 22th day of November 2006 and relates to a correction of the inventor designation of the United States Patent No. 6,911,461 B2. The AGREEMENT is made

Between

1. Differding; Edmond (Louvain-la Neuve, Belgium),
2. Kenda; Benoît (Emines, Belgium),
3. Lallemand; Bénédicte (Waimes, Belgium),
4. Matagne; Alain (Gerpinnes, Belgium),
5. Michel; Philippe (Beersel, Belgium),
6. Pasau; Patrick (Chastre, Belgium),
7. Talaga; Patrice (Watermael-Boitsfort, Belgium)

who have - at the filing date - been designated as "**original inventors**" for US-6,911,461 B2,

And

UCB S.A. ("UCB")
60 Allée de la Recherche
B-1070 Brussels
Belgium

UCB is the Assignee of US-6,911,461 B2.

WHEREAS

(A) Each of the **original inventors** has been designated at the filing date of the patent application as one of the joint inventors of the invention or inventions entitled :

"2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing them and their Uses"

and identified by the UCB reference number 17.02 US DIV 2 ("the Invention");

(B) At the time the Invention was made, the original inventors were employed by UCB; whereby

(B-1) The original inventors acknowledge that their contribution (inventive or not) made to the Invention was part of their normal duties as UCB's employees and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his duties;

(B-2) The original inventors acknowledge that Insofar as the rights in the Invention, any improvement thereof and the Application have already passed by operation of law to UCB.

(C) It is the wish and intention of all the parties hereto that

(i) US-6,911,461 B2 is exclusively owned by UCB,

(ii) US-6,911,461 B2 remains a valid and enforceable patent

IT HAS BEEN UNANIMOUSLY AGREED AND DETERMINED

1. Following a good faith examination, it was determined that the invention(s) claimed in US-6,911,461 B2 were solely conceived and reduced to practice by the 2 following inventors :

   (i) Benoît KENDA

   (ii) Patrick PASAU

   (iii) Bénédicte LALLEMAND

2. As a result of this examination the original designation of inventors of US-6,911,461 B2 needs and shall be corrected.

3. Those original inventors of US-6,911,461 B2 who have now turned out and are acknowledged not to be true inventors have no rights outstanding.

4. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with the laws of Belgium;

IN WITNESS whereof, the undersigned have caused this agreement to be duly executed on the day and year first above written.

Signed for Agreement by the original inventors: Differding; Edmond, Kenda; Benoit, Lallemand; Benedicte, Matagne; Alain, Michel; Philippe, Pasau; Patrick, Talaga; Patrice

Signature : _____ _____

Edmond Differding; PhD — Benoît Kenda; PhD

Signature : _____ _____

Bénédicte Lallemand; ~~PhD~~ — Alain Matagne; ~~PhD~~ Licenciée en Sc. Chim. ITSc.

Signature : _____ _____

Philippe Michel; PhD — Patrick Pasau; PhD

Signature : _____

Patrice Talaga; PhD

Signed for and on behalf of UCB

By: Name : Allen NORRIS

Title : Authorized Representative of UCB

Signature : _____

OIPE IAP59
APR 0 5 2007
PATENT & TRADEMARK OFFICE

PTO/SB/96 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: UCB PHARMA, S.A.

Application No./Patent No.: 6,911,461 Filed/Issue Date: June 28, 2005

Entitled: 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES

UCB PHARMA, S.A., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. [X] the assignee of the entire right, title, and interest; or

2. [ ] an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____%)

in the patent application/patent identified above by virtue of either:

A. [ ] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. [X] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: UCB, S.A.
The document was recorded in the United States Patent and Trademark Office at
Reel 013356, Frame 172, or for which a copy thereof is attached.

2. From: UCB, S.A. To: UCB PHARMA, S.A.
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

[ ] Additional documents in the chain of title are listed on a supplemental sheet.

[X] As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (*i.e.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Warren M. Cheek, Jr. — Signature
4-5-07 — Date
Warren M. Cheek, Jr. — Printed or Typed Name
202-721-8200 — Telephone Number
Attorney of record — Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.